{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:08:40Z","timestamp":1793318920977,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jfma.2026.09.015","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:32:34Z","timestamp":1789471954000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Expanding treatment guidelines for chronic hepatitis B: A narrative review"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9890-7596","authenticated-orcid":false,"given":"Chih-Lin","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2026.09.015_bib1","series-title":"Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection [Internet]","year":"2024"},{"issue":"10258","key":"10.1016\/j.jfma.2026.09.015_bib2","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2026.09.015_bib3","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2026.09.015_bib4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.5009\/gnl240023","article-title":"Toward a functional cure for hepatitis B","volume":"18","author":"Lok","year":"2024","journal-title":"Gut Liver"},{"key":"10.1016\/j.jfma.2026.09.015_bib5","series-title":"Combating hepatitis B and C to reach elimination by 2030","year":"2025"},{"key":"10.1016\/j.jfma.2026.09.015_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2026.09.015_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2026.09.015_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/HEP.0000000000001549","article-title":"AASLD ISDA practice guideline on treatment of chronic hepatitis B","volume":"83","author":"Ghany","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2026.09.015_bib9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL clinical practice guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2026.09.015_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70545","article-title":"Indeterminate phase\/grey zone of chronic hepatitis B: clinical features, outcomes and molecular insights","volume":"46","author":"Franz\u00e8","year":"2026","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2026.09.015_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/CLD.0000000000000228","article-title":"Should we expand treatment initiation criteria for chronic HBV infection: pros","volume":"23","author":"Lin","year":"2024","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jfma.2026.09.015_bib12","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021436","article-title":"HBV genotypes and variants","volume":"5","author":"Lin","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jfma.2026.09.015_bib13","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/liv.13142","article-title":"Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis","volume":"36","author":"Raffetti","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2026.09.015_bib14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/hep.26385","article-title":"Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles","volume":"58","author":"Lee","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2026.09.015_bib15","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/gutjnl-2020-323153","article-title":"Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma","volume":"71","author":"P\u00e9neau","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2026.09.015_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/sjg.sjg_279_23","article-title":"Gray zone of hepatitis B virus infection","volume":"30","author":"Lim","year":"2024","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.jfma.2026.09.015_bib17","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3350\/cmh.2026.0697","article-title":"Comparison of clinical practice guidelines for chronic hepatitis B: natural history classification and treatment initiation","volume":"32","author":"Kim","year":"2026","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jfma.2026.09.015_bib18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/HEP.0000000000001313","article-title":"Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients","volume":"83","author":"Tseng","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2026.09.015_bib19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/HEP.0000000000000752","article-title":"Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: a multinational cohort study of HBeAg-positive patients","volume":"80","author":"Choi","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2026.09.015_bib20","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1136\/gutjnl-2025-334911","article-title":"Hepatitis B surface antigen level identifies patients with inactive chronic hepatitis B from Asia with HCC risk below surveillance threshold","volume":"74","author":"Tseng","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2026.09.015_bib21","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1136\/gutjnl-2025-335033","article-title":"Differential HCC risk among HBV indeterminate types at baseline and by phase transition","volume":"74","author":"Huang","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2026.09.015_bib22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/HEP.0000000000001354","article-title":"Increased risk of HCC in HBeAg-negative indeterminate phase compared with HBeAg-negative chronic infection","volume":"83","author":"Hui","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2026.09.015_bib23","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2036.2008.03816.x","article-title":"Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma","volume":"28","author":"Sung","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2026.09.015_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2893.2009.01070.x","article-title":"Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis","volume":"16","author":"Yang","year":"2009","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2026.09.015_bib25","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1365-2036.2010.04447.x","article-title":"Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B","volume":"32","author":"Wong","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2026.09.015_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106192","article-title":"Long-term effects of peginterferon-based therapy versus nucleos(t)ide analogue monotherapy in non-cirrhotic HBeAg-positive chronic hepatitis B patients","volume":"240","author":"Hu","year":"2025","journal-title":"Antivir Res"},{"key":"10.1016\/j.jfma.2026.09.015_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/apt.14683","article-title":"Review article: the prevention of hepatitis B-related hepatocellular carcinoma","volume":"48","author":"Lin","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2026.09.015_bib28","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.15499","article-title":"Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis","volume":"50","author":"Liu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2026.09.015_bib29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/infdis\/jiy391","article-title":"Reduced incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with tenofovir-A propensity score-matched study","volume":"219","author":"Nguyen","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2026.09.015_bib30","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/jvh.12832","article-title":"Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir","volume":"25","author":"Hsu","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2026.09.015_bib31","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","article-title":"Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2026.09.015_bib32","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1136\/gutjnl-2013-305785","article-title":"Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma","volume":"63","author":"Liu","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2026.09.015_bib33","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/apt.13634","article-title":"Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance","volume":"43","author":"Liu","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2026.09.015_bib34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jhep.2026.03.030","article-title":"RETRACT-B study group. Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B - follow-up from the RETRACT-B cohort","volume":"85","author":"Dongelmans","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2026.09.015_bib35","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2026.09.015_bib36","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/jvh.13185","article-title":"The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria","volume":"26","author":"Sinn","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2026.09.015_bib37","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.3390\/cancers13102454","article-title":"Unique features of hepatitis B virus-related hepatocellular carcinoma in pathogenesis and clinical significance","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jfma.2026.09.015_bib38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/apt.17052","article-title":"Impact of expanding hepatitis B treatment guidelines: a modelling and economic impact analysis","volume":"56","author":"Lim","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2026.09.015_bib39","article-title":"Effects of treatment of chronic hepatitis B virus infection on patient-reported outcomes","volume":"16","author":"Younossi","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2026.09.015_bib40","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/apt.16097","article-title":"East Asia expert opinion on treatment initiation for chronic hepatitis B","volume":"52","author":"Kao","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2026.09.015_bib41","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.cgh.2021.07.036","article-title":"Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 update","volume":"20","author":"Martin","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2026.09.015_bib42","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s12072-026-11108-1","article-title":"APASL viral elimination taskforce. APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update","volume":"20","author":"You","year":"2026","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2026.09.015_bib43","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1097\/HEP.0000000000000459","article-title":"Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase","volume":"78","author":"Huang","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2026.09.015_bib44","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jhep.2024.11.018","article-title":"Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: a systematic review and meta-analysis","volume":"82","author":"Lai","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2026.09.015_bib45","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1473-3099(20)30692-7","article-title":"Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial","volume":"21","author":"Hsu","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jfma.2026.09.015_bib46","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2468-1253(24)00431-X","article-title":"Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial","volume":"10","author":"Lim","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2026.09.015_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2025-335449","article-title":"EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection","author":"Tang","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2026.09.015_bib48","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s12072-025-10785-8","article-title":"Expanding treatment indications in chronic hepatitis B: should we treat all patients?","volume":"19","author":"Hui","year":"2025","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2026.09.015_bib49","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/hep4.1247","article-title":"Adherence to nucleos(t)ide analogue therapies for chronic hepatitis B infection: a systematic review and meta-analysis","volume":"2","author":"Ford","year":"2018","journal-title":"Hepatol Commun"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966462600882X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966462600882X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:41:46Z","timestamp":1789591306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092966462600882X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":49,"alternative-id":["S092966462600882X"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2026.09.015","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding treatment guidelines for chronic hepatitis B: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2026.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}